Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Key Points

• GLP-1 weight-loss drugs are creating a potential tailwind for surgical aesthetics, as patients losing significant weight seek solutions for loose skin. Apyx says non-invasive treatment demand has declined while interest in skin tightening and body contouring has increased.
• AYON expands Apyx’s body-contouring portfolio by combining liposuction, fat transfer, Renuvion skin contraction and other surgical technologies. Early physician feedback suggests the system may reduce procedure times by about 45 minutes, while its disposable components provide recurring revenue.
• Apyx raised its 2026 revenue outlook to $59 million-$60 million, with surgical aesthetics expected to grow to $54 million-$55 million. The company is prioritizing AYON and other aesthetics products, pursuing international registrations and working toward profitability.

Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Speaking at the Canaccord Genuity Growth Conference, Goodwin said GLP-1 medications initially created uncertainty for the aesthetics industry but are now expected to support demand for body contouring and skin-tightening procedures. He cited a McKinsey study indicating that 63% of patients using GLP-1 drugs are new to aesthetics.

“The next decade is probably going to be the best decade that plastic surgeons have ever seen in their careers for treating these patients,” Goodwin said.

According to Goodwin, patients who lose substantial amounts of weight may experience skin laxity that often requires a surgical intervention. He said searches related to loose skin, skin tightening, liposuction and body contouring have increased, while non-invasive therapies have declined by about 30% as patients seek treatments capable of addressing more significant laxity.

Renuvion remains a core business

Goodwin described Renuvion as the only FDA-approved device for tightening skin underneath the skin. The technology uses a small probe following liposuction procedures to apply helium plasma energy beneath the skin, which he said can contract collagen and support the formation of new collagen and elastin over time.

Renuvion was previously Apyx Medical’s primary technology platform. The system includes a capital generator with a U.S. list price of approximately $165,000 and a single-use handpiece priced at about $500, according to Goodwin. He said roughly half of the company’s 2025 revenue of about $48 million came from sales of the single-use handpiece.

The company is continuing direct-to-consumer marketing for Renuvion, with the goal of increasing awareness among consumers seeking solutions for loose or lax skin. Goodwin said Apyx has more than 100 clinical papers addressing the technology’s safety and efficacy.

AYON expands body-contouring offering

In May 2025, Apyx launched the AYON Body Contouring System, which combines multiple technologies used in surgical body contouring. Goodwin said the system includes electrosurgical capabilities, infiltration and aspiration, dual suction, ultrasound-assisted liposuction, power-assisted liposuction, Renuvion skin contraction technology and a closed-loop system for fat transfer.

The company received 510(k) clearance in May for its power liposuction handpiece, which Goodwin called the final component of the AYON offering. He said approximately 80% of body-contouring physicians use power liposuction, which is used to remove and transfer fat during procedures.

Apyx conducted a soft launch during the most recently reported quarter and shipped a limited number of power liposuction handpieces near the end of June. Goodwin said the company expects to have manufacturing capacity in place to fulfill orders for the handpiece by the end of the quarter.

The company’s ultrasound-assisted liposuction technology provides real-time feedback on tissue conditions and adjusts power automatically, according to Goodwin. He said the feature is designed to allow physicians to emulsify fat more quickly and safely than earlier technologies.

Economic model and early physician feedback

In addition to the Renuvion handpiece, AYON produces disposable revenue from tubing and canisters, which Goodwin estimated at roughly $100 per procedure. Other components are reusable but require replacement over time, he said.

• Ultrasound handpiece: about $5,000
• Power-assisted handpiece: about $15,000
• Probes: about $750 each

Goodwin said 20 AYON ambassadors have been among the first physicians to use the platform. He said physicians have highlighted the system’s potential to differentiate their practices through newer technology and to improve operating-room efficiency.

According to early feedback cited by Goodwin, physicians have reported that AYON can save approximately 45 minutes on body-contouring procedures that typically last three to four hours. He said doctors view both patient outcomes and safety as important considerations when adopting the system.

2026 guidance and expansion plans

Apyx projected 2026 revenue of $59 million to $60 million, compared with $52.8 million previously. The company expects surgical aesthetics revenue of $54 million to $55 million, versus $45 million last year, while OEM revenue is projected to decline to about $5 million from $7.5 million.

Goodwin said the OEM decline is intentional, as Apyx allocates more manufacturing capacity to AYON and its surgical aesthetics products. The company expects operating expenses of no more than $45 million and is working to reach profitability as quickly as possible. He said the company’s EBITDA loss over the last four reported quarters was about $400,000.

AYON is currently sold only in the United States, but Apyx is pursuing registrations in other markets. Goodwin said the company has received international interest in the system. He also pointed to recent strength in Renuvion generator sales outside the U.S., particularly in Korea and China, with Korea representing a newer market for the company.

Looking ahead, Goodwin said Apyx intends to expand its clinical evidence base for AYON, including studies focused on procedural efficiency and fat viability. He said the company also may seek to add technologies that fit within its surgical aesthetics strategy.

About Apyx Medical (NASDAQ:APYX)

Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source